Effect of HF rTMS on Serum BDNF in Cocaine Use Disorder

Официальное название

Effects of 5-Hz Repetitive Transcranial Magnetic Stimulation on Serum Brain Derived Neurotrophic Factor and Clinical Variables in Cocaine Use Disorder

Обзор

This study aims to explore the effect of 5-Hz rTMS over the left dorsolateral prefrontal cortex on the BDNF, craving and cognitive function. This study will be longitudinal, with a short-term double-blind placebo-controlled phase consisting of 20 rTMS sessions and a long-term phase, consisting of 2 weekly sessions for 12 weeks. Participants will be clinically assessed pre-treatment (T0), after 20-sessions phase (T1) and after 12-weeks phase (T2) by an interview about psychiatric symptoms. Also, blood will be obtained in the same T0, T1 and T2 to peripheral levels of BDNF determination. Cognitive state will be measured at the same time-points (T0, T1, T2) by paper-pencil and computerized neuropsychological assessment. Researchers will compare active rTMS versus placebo 5 Hz-rTMS on described variables. Additionally, a comparative group (without rTMS intervention) will be included to equivalently measure described variables during periods without cocaine consumption.

Подробное описание

Brain derived neurotrophic factor (BDNF) is a widely explored neurotrophin in preclinical models of cocaine addiction with relevant phase and region dependent dynamics along addictive cycle. In humans with cocaine use disorder (CUD), peripheral BDNF have revealed relationship with relevant treatment outcomes as relapse and time of abstinence. In CUD several interventional studies using high frequency repetititve transcranial magnetic stimulation (rTMS) have shown craving reduction, mood improvements and sustained modifications in functional conectivity measued by fMRI. Due to the relevance of BDNF in CUD, and neuroplasticity-related processes derived from rTMS interventions, this study aims to determine changes in peripheral BDNF, craving, cognition in CUD in reponse to rTMS. Aditionally, other outcomes will be considered as depression, anxiety and motivational changes.

Procedure: Psychiatric clinical and cognitive assessment, and blood collection will be performed at T0, T1 and T2 time-points. Short-term rTMS phase will consist of two weeks (weekdays) with 2 rTMS or rTMS-placebo sessions (detaills in arms section). Then, two sessions per week along 12 weeks as maintenance therapy will be considered. No rTMS group will attend the same time points and assessment in a controlled facility.

Вмешательства

• Устройство rTMS
  Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.

Первичные конечные точки

• BDNF [Срок оценки: T0 before the intervention, T1: after rTMS 2 weeks, T2: after 12 weeks maintenance phase]
• Cocaine craving [Срок оценки: T0 before the intervention, T1: after rTMS 2 weeks, T2: after 12 weeks maintenance phase]

Вторичные конечные точки (2)

• Depression [Срок оценки: T0 before the intervention, T1: after rTMS 2 weeks, T2: after 12 weeks maintenance phase]
• Anxiety [Срок оценки: T0 before the intervention, T1: after rTMS2 weeks, T2: after 12 weeks maintenance phase]

Критерии участия

Критерии включения

• Current cocaine use disorder according to the Diagnostic and statistical manual of mental disorders (DSM 5).
• Cocaine crack or powder use for at least 12 months with a frequency of 3 times or more per week, with abstinence periods shorter than 1 year for the last year.
• Primary school completed.

Критерии исключения

• Personal or first degree family history of any neurological disorder including, but not limited to, organic brain syndrome, epilepsy, brain injuries, multiple sclerosis, conditions that increase intracranial pressure.
• Personal history of brain surgery or traumatic brain injury.
• Comorbilities that could represent a risk of neuroinfection or increased convulsive threshoid.
• Other than alcohol, tobacco or marijuana substance use disorder.
• If the patient does not meet the safety criteria for rTMS.
• Current use of any medication that might provoque seizures or any anticonvulsant drugs.
• Personal history of schizophrenia, mania/hypomania or OCD.
• Personal history of myocardial infarction, angina, congestive heart failure, cerebrovascular events, transient ischemic attack or any other heart condition currently undergoing medical treatment.
• Personal history of seizures or detection of paroxysmal EEG activity.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Двойное слепое

Основная цель

Лечение

Центры проведения

Мексика · 1 центр

• Instituto Nacional de Psiquiatría Ramón de la Fuente M. — Mexico City

Идентификаторы

NCT: NCT06189690 · TMS-Coc-BDNF

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗